As a possible alternate to existing in vitro assays of cell-mediated host responsiveness to tumour, a modification of the leucocyte adherence inhibition test employing peripheral blood lymphocytes (PBL), has been evaluated in patients with adenocarcinoma of the prostate. PBL from patients with prostatic cancer reacted to varying degrees with 3 m KCl extracts of autologous and allogeneic prostatic tumours when cultured in the presence of homologous serum. When sensitized PBL and tumour extract were cultured in autologous serum, inhibition (‘blocking’) of the interaction of PBL and antigen was observed. ‘Blocking’ was not observed when the tumour extract was allogeneic with respect to the origin of PBL and serum. Cross-reactivity between individual tumours within a given tumour type is in keeping with observations of anti-tumour immunity in patients with other tumours. Observations suggestive of a specificity of ‘blocking’ for autologous tumour only, is somewhat unique and will require further confirmation. While preliminary, these results provide further evidence suggestive of anti-tumour cell-mediated immunity in prostatic cancer patients previously observed by inhibition of leucocyte migration. The observed ‘blocking’ effect of autologous serum may be analogous to that observed in the technically more complex colony inhibition and lymphocyte cytotoxicity tests and may be indicative of one means by which the potential effects of sensitized PBL are inhibited in vivo.

Keywords:
Anti-tumour cell-mediated immunity, ‘Blocking’ factor (antibody), Cellular responsiveness, Leucocyte adherence inhibition, Prostatic cancer
This content is only available via PDF.
© 1976 S. Karger AG, Basel
1976
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.